India's Zenotech Ups Noise Against Daiichi Sankyo; Demands $20 Million In Damages

MUMBAI - The founders of India's emerging oncology and biologics company Zenotech Labs have alleged that Japanese firm Daiichi Sankyo - which holds a 47 percent equity stake in the company - destroyed the value of the company besides delaying clinical trials of one of its key oncology drugs and claiming Zenotech's product trademarks as its own. Zenotech has claimed $20 million in damages from Daiichi Sankyo at an Indian court of law